Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Intravenous (IV) Compounding Robots Market Set To Climb From $0.58 Billion In 2026 To $0.99 Billion By 2030
The intravenous (IV) compounding robots market has seen substantial growth over recent years. Its value is anticipated to rise from $0.51 billion in 2025 to $0.58 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.5%. This historical expansion can be attributed to a heightened emphasis on medication safety in hospitals, the increasing occurrence of chemotherapy drug preparation, greater integration of pharmacy automation systems, the development of centralized hospital pharmacies, and the ongoing necessity to lessen human compounding errors.
The intravenous (IV) compounding robots market is anticipated to experience significant expansion over the next few years, with its size projected to reach $0.99 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 14.2%. This growth within the forecast period can be attributed to a heightened demand for the secure handling of hazardous drugs, an increasing uptake of automated sterile compounding, growing investments in hospital automation infrastructure, the expansion of oncology treatment centers, and a rising need for operational efficiency in pharmacy workflows. Noteworthy trends during this period include technology-led innovations in robotic drug compounding, advancements in artificial intelligence (AI)-enabled dose verification, developments in closed system transfer integration, increasing research and development in precision pharmacy robotics, and innovations in real-time monitoring and quality assurance systems.
Get A Free Sample Report With In-Depth Market Insights:
Intravenous (IV) Compounding Robots Market Expansion Drivers: What’s Shaping Future Growth?
The rising number of pharmaceutical clinical trials is projected to fuel the expansion of the intravenous (IV) compounding robots market in the future. These trials are structured research studies designed to assess the safety, effectiveness, and appropriate dosage of new drugs or therapies in human participants. The growing demand for innovative treatments for intricate and emerging health conditions is contributing to the increase in pharmaceutical clinical trials. IV compounding robots assist clinical trials by guaranteeing the accurate and uniform preparation of investigational drugs, thereby improving the safety and dependability of study outcomes. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the number of pharmaceutical industry trials launched in the UK rose for the second year in a row, from 411 in 2022 to 426 in 2023. Consequently, the increasing number of pharmaceutical clinical trials is boosting the growth of the intravenous (IV) compounding robots market. The expanding adoption of personalized medicine and complex infusion protocols is anticipated to drive the intravenous (IV) compounding robots market forward. Personalized medicine involves customizing medical treatments, including drug choice and dosage, based on individual patient characteristics like genetics, biomarkers, and disease profiles. The increasing approval and clinical implementation of targeted therapies that necessitate highly customized intravenous dosing and preparation are propelling the growth of personalized medicine. IV compounding robots support personalized medicine by automating the precise preparation and individualized dosing of high-potency therapies, ensuring accuracy, safety, and consistency for patient-specific treatments. For instance, in November 2025, the Personalized Medicine Coalition, a US-based nonprofit organization, stated that the US Food and Drug Administration approved 18 new personalized medicines in 2024, making up over 25% of all new drug approvals, following 20 personalized medicine approvals in 2023, many of which require individualized IV preparation. Thus, the expanding use of personalized medicine and complex infusion protocols is propelling the growth of the intravenous (IV) compounding robots market.
Intravenous (IV) Compounding Robots Market Segment Performance And Emerging Opportunities
The intravenous (iv) compounding robots market covered in this report is segmented –
1) By Component: Hardware, Software, Consumables
2) By Product Type: Centralized Robots, Decentralized Robots
3) By Technology: Gravimetric Dosing Systems, Volumetric Dosing Systems, Hybrid Dosing Systems
4) By Application: Chemotherapy, Parenteral Nutrition, Monoclonal Antibodies, Other Applications
5) By End User: Hospitals, Oncology Centers, Compounding Pharmacies, Other End Users
Subsegments:
1) By Hardware: Robotic Arms, Control Panels, Safety Enclosures, Sensors
2) By Software: Workflow Management Software, Dose Verification Software, Inventory Management Software, Reporting And Analytics Software
3) By Consumables: Syringes, Vials, Needles
Intravenous (IV) Compounding Robots Market Strategic Trends: What Defines The Next Growth Phase?
Major companies in the intravenous (IV) compounding robots market are developing innovative central pharmacy dispensing robots to enhance accuracy, safety, and efficiency in intravenous drug preparation, support personalized medicine, and reduce occupational exposure to high-potency and hazardous drugs. These central pharmacy dispensing robots are automated systems designed to store, retrieve, and dispense medications efficiently and accurately within a hospital or pharmacy setting, reducing errors and improving workflow. For instance, in October 2025, Ballad Health, a US-based healthcare company, launched three compounding robots for its central fill pharmacy at Bristol (Tenn.) Regional Medical Center. The implementation of these robots allows Ballad Health to streamline workflow, reduce turnaround time for IV medication preparation, and support personalized treatment protocols. This adoption also reinforces the hospital’s commitment to patient safety and regulatory compliance in handling hazardous drugs.
Intravenous (IV) Compounding Robots Market Company Landscape And Competitive Strategy
Major companies operating in the intravenous (iv) compounding robots market are Becton Dickinson and Company, Baxa Corporation, Grifols Engineering S.A., IMA Life S.p.A., ICU Medical Inc., Syntegon Technology GmbH, Omnicell Inc., OPTIMA Pharma GmbH, Marchesini Group S.p.A., Romaco Group, Trasis S.A., APOTECA S.p.A., ARxIUM Inc., Health Robotics S.r.l., Steriline Robotics, PharmaSmart Robotics, iPharma Automation, Robotic Automation Systems, Pharma Automation Solutions, Aesynt Inc., Aseptio Technologies LLC
View The Full Intravenous (IV) Compounding Robots Market Report:
Intravenous (IV) Compounding Robots Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the intravenous (IV) compounding robots market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous (iv) compounding robots market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
